Can Transcriptional Regulation Be Targeted for Cancer Therapy?
Yes, targeting transcriptional regulation offers promising therapeutic opportunities. Small molecules that inhibit specific transcription factors or epigenetic modifiers are being developed. For instance, inhibitors of the BET family of bromodomain proteins, which regulate gene expression through histone acetylation, have shown efficacy in preclinical cancer models. Additionally, epigenetic drugs such as DNA methyltransferase inhibitors and histone deacetylase inhibitors are already in clinical use for certain cancers.
